Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 18, Issue 3, Pages 257-268Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2014.863876
Keywords
antibodies; cytokines; herbal component; HMGB1; innate immune cells; PKR; sepsis
Categories
Funding
- National Center of Complementary and Alternative Medicine (NCCAM) [R01AT005076]
- National Institute of General Medical Sciences (NIGMS) [R01GM063075]
Ask authors/readers for more resources
Introduction: Sepsis refers to the host's deleterious and non-resolving systemic inflammatory response to microbial infections and represents the leading cause of death in the intensive care unit. The pathogenesis of sepsis is complex, but partly mediated by a newly identified alarmin molecule, the high mobility group box 1 (HMGB1). Areas covered: Here we review the evidence that support extracellular HMGB1 as a late mediator of experimental sepsis with a wider therapeutic window and discuss the therapeutic potential of HMGB1-neutralizing antibodies and small molecule inhibitors (herbal components) in experimental sepsis. Expert opinion: It will be important to evaluate the efficacy of HMGB1-targeting strategies for the clinical management of human sepsis in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available